Setsuko K Chambers MD

Obstetrics & Gynecology•Tucson, AZ

General Gynecology, Gynecologic Oncology

Professor of Obstetrics & Gynecology, University Ariz College of Medicine

Join to View Full Profile

3838 N Campbell AveTucson, AZ 85719
Phone+1 520-694-8888
Fax+1 520-694-0348

Education & Training

Yale-New Haven Medical CenterFellowship, Gynecologic Oncology, 1984 - 1986
Yale-New Haven Medical CenterResidency, Obstetrics and Gynecology, 1980 - 1984
The Warren Alpert Medical School of Brown UniversityClass of 1980

Certifications & Licensure

AZ State Medical License 2004 - 2026
CT State Medical License 1984 - 2004
IL State Medical License 1983 - 1984
American Board of Obstetrics and Gynecology Obstetrics & Gynecology
American Board of Obstetrics and Gynecology Gynecologic Oncology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2008-2014
Top Doctors:Arizona State Castle Connolly, 2013
America's Top Doctors for Cancer Castle Connolly, 2007-2013
Elected Member Institute of Medicine, 2009
Fellow (FACOG) American Congress of Obstetricians and Gynecologists
Join now to see all

Clinical Trials

Effect of Flutamide on Biomarkers in Blood and Tissue Samples From Patients at High Risk of Ovarian Cancer Start of enrollment: 2005 Jan 01
Completed
Phase 2
Alimta® Plus Cisplatin & Paclitaxel Given Intraperitonelly; First Line Tx Stage III Ovarian Cancer Start of enrollment: 2007 Sep 01
Completed
Phase 1
Open Trial of Bendamustine Hydrochloride in Women With Advanced Ovarian Cancer Start of enrollment: 2009 Feb 01
Completed
Phase 2
Arizona Cancer Center Biospecimen Repository
RECRUITING
Lymphedema After Surgery in Patients With Endometrial Cancer, Cervical Cancer, or Vulvar Cancer Start of enrollment: 2012 Jun 01
Unknown status
Not Applicable
Evaluation of Carboplatin/Paclitaxel With and Without Trastuzumab (Herceptin) in Uterine Serous Cancer Start of enrollment: 2011 Jun 01
Completed
Phase 2
A Phase II Evaluation of Afatinib in Patients With Persistent or Recurrent HER2-positive Uterine Serous Carcinoma
RECRUITING
PHASE2
Roles: Contact
Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer Start of enrollment: 2022 Sep 28
ACTIVE_NOT_RECRUITING
PHASE2
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

1 citations
miR-449, identified through antiandrogen exposure, mitigates functional biomarkers associated with ovarian cancer risk.
Xia Wang, Ho-Hyung Woo, Michelle Wei, Steven Gibson, Mitzi Miranda
Scientific Reports. 2024-12-02
2 citations
Tolerability of the niraparib individualized starting dose in the PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib first-line maintenance therapy.
Christof Vulsteke, Setsuko K Chambers, Maria Jesús Rubio Pérez, John K Chan, Nicoline Raaschou-Jensen
European Journal of Cancer. 2024-09-01
Antiandrogen Flutamide-Induced Restoration of miR-449 Expression Mitigates Functional Biomarkers Associated with Ovarian Cancer Risk.
Xia Wang, Ho-Hyung Woo, Michele Wei, Steven Gibson, Mitzi Miranda
Medrxiv. 2024-02-29

Grant Support

Regulation Of CSF-1 In Ovarian CancerNational Cancer Institute2004–2006
Regulation Of CSF-1 In Ovarian CancerNational Cancer Institute2002–2003
Regulation Of CSF 1 And Urokinase In Ovarian CancerNational Cancer Institute1995–1999
Regulation Of C-FMS Proto-Oncogene In Epithelial CancersEunice Kennedy Shriver National Institute Of Child Health &Human Development1993–1995
Contemporary Approaches To Ovarian CancerNational Cancer Institute1993
CSF-1 And Drug Resistance In Reproductive CancersEunice Kennedy Shriver National Institute Of Child Health &Human Development1990–1991

Professional Memberships

American College of Obstetricians and Gynecologists
Fellow